SCHEDULE: Vanguard Discloses 4.2% Stake in RAPT Therapeutics

The Vanguard Group reported a 4.2% beneficial ownership stake in RAPT Therapeutics Inc. common stock as of September 30, 2025.

Summary

• The Vanguard Group beneficially owns 696,188 shares of RAPT Therapeutics Inc. common stock.
• This ownership represents 4.2% of the company's outstanding common stock.
• The filing indicates that Vanguard holds 0 shares with sole voting power, 60,162 shares with shared voting power, 630,832 shares with sole dispositive power, and 65,356 shares with shared dispositive power.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• The Vanguard Group is classified as an investment adviser (IA) for the purpose of this filing.

Sentiment

Score: 6

Explanation: The filing indicates a significant institutional holding by The Vanguard Group, which is generally a positive signal of investor interest and liquidity, though it is a routine disclosure without specific performance data.

Positives

• The disclosure of a 4.2% stake by a major institutional investor like The Vanguard Group indicates institutional interest and confidence in RAPT Therapeutics Inc.
• Vanguard's holding of shares in the ordinary course of business suggests a long-term, passive investment strategy, which can provide stability to the shareholder base.

Negatives

• The filing itself does not contain any negative information regarding RAPT Therapeutics Inc.; it is purely a disclosure of ownership by an institutional investor.

Risks

• The filing does not explicitly mention specific risks related to RAPT Therapeutics Inc. or its operations, as it is a disclosure of beneficial ownership by an institutional investor.

Future Outlook

This filing does not provide any forward-looking statements or guidance regarding RAPT Therapeutics Inc.'s future performance or strategic direction, as it is a disclosure of beneficial ownership by an institutional investor.

Industry Context

The disclosure of a significant stake by a major asset manager like The Vanguard Group is a common occurrence in the public markets, reflecting routine portfolio management and investment in publicly traded companies. For a biotechnology company like RAPT Therapeutics, institutional ownership can be a positive signal of market liquidity and investor interest in the sector.

Comparison to Industry Standards

• The Vanguard Group is one of the world's largest investment management companies, and its holdings in various public companies, including those in the biotechnology sector, are standard practice for its index and actively managed funds. A 4.2% stake is a typical passive investment size for such an institution, not indicative of an activist position.
• Comparable institutional holdings in other biotech firms often see similar passive stakes from large asset managers like BlackRock, State Street, or Fidelity, reflecting broad market exposure rather than specific strategic intent.

Stakeholder Impact

• Shareholders may view The Vanguard Group's significant stake as a positive indicator of institutional confidence and liquidity in RAPT Therapeutics Inc. stock.
• The presence of a large, passive institutional investor can contribute to market stability and trading volume for the company's shares.

Key Dates

Recommendation

This Schedule 13G filing primarily discloses a passive ownership stake by The Vanguard Group. While institutional interest is generally a positive signal, the filing itself does not provide sufficient fundamental or operational information about RAPT Therapeutics Inc. to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' their positions and consider this information as part of a broader analysis of the company's financial health, pipeline, and market position.

Keywords

RAPT Therapeutics, Vanguard Group, SEC Filing, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, Pharmaceuticals